UnknownNot Applicable

Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections

France70 participantsStarted 2022-11-21

Plain-language summary

Carbapenemase-producing Enterobacteriaceae (CPE) infections are emerging infections that pose a therapeutic challenge. These infections mainly occur in patients with prolonged hospitalization and repeated exposure to antibiotics. Certain strains, notably VIM-producing strains, may remain sensitive to carbapenems. CPE VIM strains are rare in France, but represent the main CPE strains in many countries. They are historically the main type of carbapenemases isolated at the Strasbourg University Hospital.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patient (≥18) * Treated at the HUS for a VIM-producing enterobacteria infection between 01/01/2011 and 11/30/2022 * Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes. Exclusion Criteria: * Patient having expressed his opposition to the retrospective reuse of his data for scientific research purposes.

What they're measuring

Mortality at 28 days

Timeframe: Mortality at 28 days after infection

Trial details

NCT IDNCT06185153

SponsorUniversity Hospital, Strasbourg, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12

Contact for this trial

Baptiste HOELLINGER, MD

33 3 69 55 05 45 baptiste.hoellinger@chru-strasbourg.fr

View on ClinicalTrials.gov More Carbapenemase-Producing Enterobacteriaceae trials